

# Opioid Weaning

## Withdrawal Prevention/Wean Algorithm Evidence Based Outcome Center



- Monitor all patients for withdrawal/oversedation and manage accordingly. Modify weans per algorithm if patient has symptoms of withdrawal.
- When weaning multiple medications, ensure doses of medications are timed to prevent overlap in administration to avoid the risk of oversedation.
- In weaning ultra-high-risk patients, please consult with the pharmacy, as certain patients may need a more gradual wean.

### Risk Criteria: Weaning course relative to duration of continuous infusions

- **Minimal ( ≤ 3 days):** No wean necessary. Monitor for withdrawal and use PRNs as needed
- **Low-Risk ( > 3 to 5 days):** Wean infusion(s) off over 24 hours. Monitor for withdrawal and use PRNs as needed
- **Moderate Risk ( > 5 to 10 days):** Use below conversions and follow directions below
- **High Risk ( > 10 to 21 days):** Use below conversions and follow directions below
- **Ultra High Risk ( > 21 days):** Use below conversions and follow directions below

### Opioid Conversion: Convert current IV infusion dose to equivalent enteral therapy

**FENTANYL:** Multiply current fentanyl drip rate (mcg/kg/HR) X 0.05 = \_\_\_\_\_ mg/kg/dose enteral methadone q6h (max dose 0.2 mg/kg/dose or 10 mg/dose)

**HYDROMORPHONE:** Multiply current hydromorphone drip rate (mg/kg/HR) X 3.4 = \_\_\_\_\_ mg/kg/dose enteral methadone q6h (max dose 0.2 mg/kg/dose or 10 mg/dose)

**MORPHINE:** Multiply current morphine drip rate X 0.5 = \_\_\_\_\_ mg/kg/dose enteral methadone q6h (max dose 0.2 mg/kg/dose or 10 mg/dose)

Methadone  
IV to ENTERAL  
= 0.8 to 1

#### Moderate Risk Patients –

**Infusion wean:** Starting with 2<sup>nd</sup> dose methadone wean infusion by 25% after every dose

**Enteral wean:** Once stable on methadone for 24h, move to next step

#### High Risk Patients –

**Infusion wean:** Starting with 2<sup>nd</sup> dose methadone wean infusion by 25% after every/ every other dose

**Enteral wean:** Once stable on methadone for 48h, move to next step

Step 1 -	Wean to 80% of starting dose and divide q6h x 4 doses
Step 2 -	Continue same dose, change frequency to q8h x 3 doses
Step 3 -	Continue same dose, change frequency to q12h x 2 doses
Step 4 -	Continue same dose, change frequency to q24h x 1 dose
Step 5 -	If needed, decrease dose by 50% q24h x 1 dose

Step 1 -	Wean to 80% of starting dose and divide q6h x 8 doses
Step 2 -	Continue same dose, change frequency to q8h x 6 doses
Step 3 -	Continue same dose, change frequency to q12h x 4 doses
Step 4 -	Continue same dose, change frequency to q24h x 2 doses
Step 5 -	If needed, decrease dose by 50% q24h x 2 doses

#### Ultra High Risk Patients –

**Infusion wean:** After 2<sup>nd</sup> or 3<sup>rd</sup> dose methadone wean infusion by 10-20 % after every other dose

**Enteral wean:** Once stable on methadone for 48h wean to the next step

Step 1 -	Wean to 90% of the total daily starting dose and divide q6h x 8 doses
Step 2 -	Wean to 80% of the total daily starting dose and divide q6h x 8 doses
Step 3 -	Wean to 70% of the total daily starting dose and divide q6h x 8 doses
Step 4 -	Wean to 60% of the total daily starting dose and divide q6h x 8 doses
Step 5 -	Wean to 50% of the total daily starting dose and divide q6h x 8 doses
Step 6 -	Wean to 40% of the total daily starting dose and divide q6h x 8 doses
Step 7 -	Continue same dose, wean frequency to q8h x 6 doses
Step 8 -	Continue same dose, wean frequency to q12h x 4 doses
Step 9 -	Continue same dose, wean frequency to q24h x 4 doses
Step 10 -	If needed, decrease dose by 50% q24h
Step 11 -	OFF

Due to methadone's longer half-life, some providers may consider consolidating the same TOTAL daily dose earlier to less frequent dosing (e.g., moving from q6h to q8h, then q12h more rapidly). However, this should be done cautiously as higher, less frequent doses can lead to oversedation. Please contact your pharmacist for assistance.

- Monitor all patients for withdrawal/oversedation and manage accordingly. Modify weans per algorithm if patient has symptoms of withdrawal.
- When weaning multiple medications, ensure doses of medications are timed to prevent overlap in administration to avoid the risk of oversedation.
- In weaning ultra-high-risk patients, please consult with the pharmacy, as certain patients may need a more gradual wean.

**Risk Criteria:** Weaning course relative to duration of continuous infusions

- **Minimal ( ≤ 3 days):** No wean necessary. Monitor for withdrawal and use PRNs as needed.
- **Low-Risk ( > 3 to 5 days):** Wean Dexmedetomidine off over 24 hours, monitor for withdrawal with WAT-1 and use PRNs as needed.
- **Moderate Risk ( > 5 to 10 days):** Use conversion and follow directions below.
- **High Risk ( > 10 to 21 days):** Use conversion and follow directions below.
- **Ultra High Risk ( > 21 days):** Use conversion and follow directions below.

### Alpha agonist (Dexmedetomidine ) Conversion

- Dex infusion < 0.5 mcg/kg/HR, use 4 mcg/kg/DAY clonidine enteral, divided every 6 hours (Max dose 0.1 mg/dose)
- Dex infusion > 0.5 - 1 mcg/kg/HR, use 8 mcg/kg/DAY clonidine enteral, divided every 6 hours (Max dose 0.2 mg/dose)
- Dex infusion > 1 - 1.5 mcg/kg/HR, use 10 mcg/kg/DAY clonidine enteral, divided every 6 hours (Max dose 0.3 mg/dose)
- Dex infusion > 1.5 mcg/kg/HR, consider weaning to < 1.5 mcg/kg/HR if hemodynamically unstable or use clonidine 12 mcg/kg/DAY divided every 6 hours (Max dose 0.3mg/dose)

See Guidelines for Clonidine patch alternative

#### Moderate Risk Patients –

**Infusion wean:** Starting with 2<sup>nd</sup> dose Clonidine wean infusion by 25% after every dose

**Enteral wean:** Once stable on clonidine for 24h, move to next step

Step 1 -	Continue same dose, wean frequency to q8h X 3 doses
Step 2 -	Continue same dose, wean frequency to q12h X 2 doses
Step 3 -	Wean dose by 50% keep frequency q12h X 2 doses
Step 4 -	Discontinue clonidine

#### High Risk Patients –

**Infusion wean:** Starting with 2<sup>nd</sup> dose Clonidine wean infusion by 25% after every/ every-other dose

**Enteral wean:** Once stable on clonidine for 48h, move to next step

Step 1 -	Continue same dose wean starting dose by 20% q6h X 8 doses
Step 2 -	Continue same dose wean frequency to q8h X 6 doses
Step 3 -	Continue same dose wean frequency to q12h X 4 doses
Step 4 -	Wean dose by 50% keep frequency q12h x 4 doses
Step 5 -	Discontinue clonidine

#### Ultra High Risk Patients –

**Infusion wean:** Starting with 2<sup>nd</sup> dose Clonidine wean infusion by 25% after every other dose

**Enteral wean:** Once stable on clonidine for 48h, move to next step

Step 1 -	Wean to 90% of the total daily starting dose and divide q6h x 8 doses
Step 2 -	Wean to 80% of the total daily starting dose and divide q6h x 8 doses
Step 3 -	Wean to 70% of the total daily starting dose and divide q6h x 8 doses
Step 4 -	Wean to 60% of the total daily starting dose and divide q6h x 8 doses
Step 5 -	Wean to 50% of the total daily starting dose and divide q6h x 8 doses
Step 6 -	Wean to 40% of the total daily starting dose and divide q6h x 8 doses
Step 7 -	Continue same dose , wean frequency to q8h x 6 doses
Step 8 -	Continue same dose , wean frequency to q12h x 4 doses
Step 9 -	Decrease dose by 50%, keep frequency continue q12h x 4 doses
Step 10 -	Discontinue clonidine

# Benzodiazepine Weaning

## Withdrawal Prevention/Wean Algorithm Evidence Based Outcome Center

- Monitor all patients for withdrawal/oversedation and manage accordingly. Modify weans per algorithm if patient has symptoms of withdrawal.
- When weaning multiple medications, ensure doses of medications are timed to prevent overlap in administration to avoid the risk of oversedation.
- In weaning ultra-high-risk patients, please consult with the pharmacy, as certain patients may need a more gradual wean.

**Risk Criteria:** Weaning course relative to duration of continuous infusions

- **Minimal ( ≤ 3 days):** No wean necessary, monitor for withdrawal, and use PRNs as needed
- **Low-Risk ( > 3 to 5 days):** Wean infusion(s) off over 24 hrs., monitor for withdrawal with WAT-1, and use PRNs as needed.
- **Moderate Risk ( > 5 to 10 days):** Use conversion and follow directions below
- **High Risk ( > 10 to 21 days):** Use conversion and follow directions below
- **Ultra High Risk ( > 21 days):** Use conversion and follow directions below

### Benzodiazepine Conversion

**BENZODIAZEPINE:** Multiply current Midazolam drip rate X 0.5 = \_\_\_\_\_ mg/kg/dose lorazepam q6h (max dose 0.2 mg/kg/dose or 4 mg/dose)

Lorazepam IV to ENTERAL = 1:1

#### Moderate Risk Patients –

**Infusion wean:** Starting with 2<sup>nd</sup> dose Lorazepam wean infusion by 25% after every dose

**Enteral wean:** Once stable on Lorazepam for 24h, move to next step

Step 1 -	Wean to 80% of starting dose and divide q6h x 4 doses
Step 2 -	Continue same dose, wean frequency to q8h x 3 doses
Step 3 -	Continue same dose, change frequency to q12h x 2 doses
Step 4 -	If needed, decrease dose by 50% q12h x 2 doses
Step 5 -	Discontinue lorazepam

#### High Risk Patients –

**Infusion wean:** Starting with 2<sup>nd</sup> dose Lorazepam wean infusion by 25% after every/ every-other dose

**Enteral wean:** Once stable on Lorazepam for 48h, move to next step

Step 1 -	Wean to 80% of starting dose and divide q6h x 8 doses
Step 2 -	Continue same dose, wean frequency to q8h x 6 doses
Step 3 -	Continue same dose, change frequency to q12h x 4 doses
Step 4 -	If needed, decrease dose by 50% q12h x 4 doses
Step 5 -	Discontinue lorazepam

#### Ultra High Risk Patients –


**Infusion wean:** Starting with 2<sup>nd</sup> dose Lorazepam wean infusion by 25% after every other dose

**Enteral wean:** Once stable on Lorazepam for 48h, move to next step

Step 1 -	Wean to 90% of the total daily starting dose and divide q6h x 8 doses
Step 2 -	Wean to 80% of the total daily starting dose and divide q6h x 8 doses
Step 3 -	Wean to 70% of the total daily starting dose and divide q6h x 8 doses
Step 4 -	Wean to 60% of the total daily starting dose and divide q6h x 8 doses
Step 5 -	Wean to 50% of the total daily starting dose and divide q6h x 8 doses
Step 6 -	Wean to 40% of the total daily starting dose and divide q6h x 8 doses
Step 7 -	Continue same dose, wean frequency to q8h x 6 doses
Step 8 -	Continue same dose, wean frequency to q12h x 4 doses
Step 9 -	Wean dose by 50 %, keep frequency q12h x 4 doses
Step 10 -	Discontinue Lorazepam

# Withdrawal / Oversedation Algorithm

## Evidence Based Outcome Center



Note: This information is a guide. Individual patients may require deviation from this guideline and clinical judgement is advised.



## Withdrawal Prevention/Wean Algorithm Evidence Based Outcome Center



### Revision History

Date Approved: March 2025  
Next Full Review: March 2029  
Revision History: 2025 – New Weaning Algorithm Published to DCMC EBOC site

### EBOC Team:

Alexandra Wilson, MD  
Claire Bundick, PharmD  
Derek Templet, PharmD  
Carmen Garudo, EBOC PM  
Additional Reviewers:  
Intensivists  
Pharmacy/ CICU Pharmacy

### EBOC Leadership Team:

Sarmistha Hauger, MD  
Patty Click, RN  
Melissa Cossey, MD  
Tory Meyer, MD  
Nilda Garcia, MD  
Meena Iyer, MD  
Amanda Puro, MD  
Lynsey Vaughan, MD

**LEGAL DISCLAIMER:** The information provided by Dell Children's Medical Center (DCMC), including but not limited to Clinical Pathways and Guidelines, protocols and outcome data, (collectively the "Information") is presented for the purpose of educating patients and providers on various medical treatment and management. The Information should not be relied upon as complete or accurate; nor should it be relied on to suggest a course of treatment for a particular patient. The Clinical Pathways and Guidelines are intended to assist physicians and other health care providers in clinical decision-making by describing a range of generally acceptable approaches for the diagnosis, management, or prevention of specific diseases or conditions. These guidelines should not be considered inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment regarding care of a particular patient must be made by the physician in light of the individual circumstances presented by the patient. DCMC shall not be liable for direct, indirect, special, incidental or consequential damages related to the user's decision to use this information contained herein.